OR

Oliver Reuss

Investment Manager at Boehringer Ingelheim Venture Fund GmbH

Germany

Overview 

Oliver Reuss is the Executive Director and Investment Manager at Boehringer Ingelheim Venture Fund, with a notable career in the pharmaceutical industry and a track record of successful product launches and company leadership. He serves on the Board of Directors for companies like Dopavision and has invested in notable ventures like Brainomix and Perfood, demonstrating expertise in Series A investments within the health and hospital services sectors.

Work Experience 

  • Executive Director / Investment Manager; Boehringer Ingelheim Venture Fund

    2018 - Current

  • Head of Business Model & HealthCare Innovation

    2014 - 2018

  • Head of Prescription Medicine Strategy & Strategic Intelligence

    2013 - 2014

  • Senior Manager PM Strategy & Portfolio Management

    2012 - 2013

  • International Business Analysis Manager

    2008 - 2011

  • Member, Board of Directors

    2025

    C-mo is a wearable cough-monitoring device that provides a comprehensive assessment of cough’s distinctive characteristics. The information provided by C-mo will allow doctors to expand their knowledge base, possess a more comprehensive and objective information set and consequently, to provide more accurate diagnosis and prescribe more tailored treatments.

  • Member, Board of Directors

    2024

    Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

  • Observer, Board of Directors

    2024

    Glox Therapeutics is developing precision, engineered protein bacteriocins to target drug-resistant pathogenic bacteria.

  • Member, Board of Directors

    2021

    Brainomix, Ltd. focuses on imaging software for neurological and cerebrovascular diseases and developed a software tool (e-ASPECTS) for the automated analysis of CT scans to detect early ischemic changes in the brain of patients with clinical signs of stroke. Currently, Brainomix utilizes its platform technology to expand into new therapeutic indications, including lung fibrosis and cancer. Brainomix is a spin-out from the University of Oxford, UK.

  • Member, Board of Directors

    2020

    Perfood develops digital therapeutics powered by proprietary technology for personalized stable-glycemic nutrition. Perfood is building a pipeline of therapeutic solutions, where its core competence of modulating the glucose metabolism and inflammatory processes add disease-specific value. Find out more on www.perfood.de

  • Member, Board of Directors

    2019

    Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. The goal is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Find out more on www.dopavision.com

  • Business Analyst

    2007 - 2008

Articles About Oliver

Relevant Websites